Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1992:284 Suppl 1:S27-9.
doi: 10.1007/BF00638237.

Therapy with topical corticosteroids

Affiliations
Review

Therapy with topical corticosteroids

W Sterry. Arch Dermatol Res. 1992.

Abstract

Therapy with topical corticosteroids has improved greatly in recent years due to both advanced understanding of their mode of action and awareness of their side effects, as well as newly developed derivatives with specifically designed pharmacological properties. Paradoxically, the fear of using corticosteroids has increased on the part of the public during the same period. Treatment of inflammatory or neoplastic skin disorders with topical corticosteroids can be both successful and safe only if certain points are clarified before it is begun. These include (a) specific diagnosis, (b) choice of strength of the compound needed for control of the disease, (c) time schedule for length of therapy and planned patient visits, and (d) choice of vehicle adequate to the skin lesion. Topical corticosteroids of different potency are available today; one can classify these into four groups (weak, medium, strong, very strong) and use them in a patient-tailored treatment. When large areas are to be treated, systemic side effects must be taken into consideration, and compounds that are degraded quickly after absorption are recommended. Finally, the corticophobia of many patients must be addressed by careful information to ensure compliance. Using these guidelines, treatment with corticosteroids is highly effective, easy to use by the patient, and allows a maximum of safety.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arch Dermatol Res. 1988;280 Suppl:S33-41 - PubMed
    1. Clin Exp Dermatol. 1983 Sep;8(5):489-93 - PubMed
    1. Br J Dermatol. 1984 Jul;111 Suppl 27:204-12 - PubMed
    1. Clin Exp Dermatol. 1985 Jan;10(1):13-21 - PubMed
    1. Br J Pharmacol. 1989 Mar;96(3):656-60 - PubMed

LinkOut - more resources